Psoriasis New Drug Milestone Up to $200 Million.. Profitable U.S. Bio, CEO Conducts Mass Sell-off

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) reported first-quarter 2026 financial results on May 5, announcing that it received a $50 million milestone payment following the U.S. Food and Drug Administration’s approval of ICOTYDE, its treatment for moderate-to-severe plaque psoriasis. The FDA has also accepted the new drug application for rusfertide under priority review, setting an August PDUFA date.

The company exercised its opt-out rights under the Takeda partnership for rusfertide, converting the deal into an upfront $200 million payment structure, with additional approval and sales milestones and royalties of up to 29%. Protagonist ended the quarter with $620.3 million in cash and cash equivalents, providing a funding runway through at least 2028.

In a separate filing, CEO Dinesh Patel exercised 75,000 stock options on May 12 and immediately sold the same number of shares in the open market, realizing approximately $5.9 million in net proceeds. He still holds more than 520,000 shares, leaving his overall stake largely unchanged.

Reflecting the momentum from the ICOTYDE launch and the revised rusfertide agreement, major brokerages including BMO Capital Markets and Truist Securities have reiterated buy ratings and raised their price targets on PTGX. Analysts are focusing on the company’s transition to a revenue model driven by milestones and royalties. Some caution that the first-quarter profitability is largely attributable to one-time milestone income and warn that upcoming approval and sales milestones, along with royalty receipts, may introduce short-term earnings volatility.

Protagonist is a biotech company specializing in oral and injectable peptide-based therapies for immune and hematologic diseases. Its late-stage pipeline is anchored by ICOTYDE for plaque psoriasis and rusfertide for polycythemia vera. Oral biologics for autoimmune conditions and drugs for rare blood disorders typically command high prices and require chronic dosing, making them attractive candidates for licensing and co-development partnerships with major pharmaceutical companies. Successful programs in these areas often generate substantial milestone payments and ongoing sales royalties.